Amazon, Marriott, Berkshire Hathaway And A Health Care Stock: CNBC’s ‘Final Trades’
CNBC final trades feature Berkshire Hathaway, Amazon, AbbVie and Marriott, backed by analyst upgrades, strong earnings and growth plans.
Last updated: 2026-11-18 16:55:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
ABBVIE INC. (ABBV) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $288.88, with a market capitalization of $520.65B and a P/E ratio of 50.10. Over the past 52 weeks, its price has ranged from $190.75 to $302.93. This page covers its latest market performance, valuation, price trends and company information.
$520.65B | |
$290.00 | |
$293.59 | |
$287.13 | |
$292.82 | |
1.39M | |
4.79M | |
50.10 | |
$302.93 | |
$190.75 | |
2.35% | |
2026-09-30 |
ABBVIE INC. (ABBV) is currently trading at $288.88 as of 2026-11-18 16:39:00, down 1.36% ($3.99) from the previous close of $292.82
During today's regular trading session, ABBV has traded between $287.13 and $293.59, with a trading volume of 1.39M shares. The current price is near the lower end of today's range.
Over the past seven days, ABBVIE INC. (ABBV) moved from $293.30 to $288.88, representing a decline of 1.51% ($4.42).
The stock traded between $287.13 and $301.20 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 4.31 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 87.5%
ABBV is currently trading at $288.88, placing it 87.5% of the way from its 52-week low of $190.75 to its 52-week high of $302.93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 57,000 |
| CEO | Robert A. Michael |
| Founded | 2012 |
| Exchange | NYSE |
| Company Website |
View the latest dividend and stock split events for ABBVIE INC.
Dividend | |
|---|---|
| Ex-Dividend Date | Jan 15, 2027 |
| Payment Date | Feb 16, 2027 |
| Dividend Per Share | $1.82 |
Latest news related to ABBVIE INC. and ABBV stock.
CNBC final trades feature Berkshire Hathaway, Amazon, AbbVie and Marriott, backed by analyst upgrades, strong earnings and growth plans.
The article compares Johnson & Johnson and Vertex Pharmaceuticals as investment options for 2027. JNJ is a diversified healthcare giant with $99.3B in revenue and strong cash flow, while VRTX is a specialized biotech leader with $13B in revenue focused on cystic fibrosis and expanding into gene therapies. Despite VRTX's higher growth rate and lower P/E ratio, JNJ is recommended as the better buy due to its superior valuation multiples (P/E 25.4x vs 29.6x, P/S 6.8x vs 10.5x) and established market position.
Natera Inc. (NASDAQ:NTRA) short sellers added to their positions as of the latest settlement date.Short interest rose 3.77% to 6.07 million shares as of the Oct. 30 settlement date, from 5.85 million at the Oct. 15
Inside Citadel's Q3 13F: Ken Griffin slashed AMD and Amazon, raised Marvell 729%, and quietly unwound Leopold Aschenbrenner's AI fund.
Eligible investors can buy real shares of ABBVIE INC. (ABBV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ABBV, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ABBV shares and USD.
ABBV Shares to USD
1.00 ABBV shares = 288.878 USD
Calculations are estimates based on the latest available price and are for reference only.